You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
ARRY 520 trifluoroacetate
Biological Activity for ARRY 520 trifluoroacetate
ARRY 520 trifluoroacetate is a potent kinesin spindle protein (KSP) inhibitor (IC50 = 6 nM); selective for KSP over >250 other receptors and kinases at a concentration of 10 μM. Displays robust antitumor activity in bortezomib-resistant xenografts either alone or in combination with bortezomib. Induces degradation of Mcl-1; exhibits comparable cytotoxic activity to taxol (Cat. No. 1097) in epithelial ovarian cancer cells. Active in vivo.
Technical Data for ARRY 520 trifluoroacetate
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for ARRY 520 trifluoroacetate
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for ARRY 520 trifluoroacetate
The following data is based on the product molecular weight 420.48. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.75 mM||3.17 mL||15.85 mL||31.71 mL|
|3.75 mM||0.63 mL||3.17 mL||6.34 mL|
|7.5 mM||0.32 mL||1.59 mL||3.17 mL|
|37.5 mM||0.06 mL||0.32 mL||0.63 mL|
Product Datasheets for ARRY 520 trifluoroacetate
References for ARRY 520 trifluoroacetate
References are publications that support the biological activity of the product.
Woessner et al (2009) ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res. 29 4373 PMID: 20032381
Tunquist et al (2010) Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol.Cancer.Ther. 9 2046 PMID: 20571074
Kim et al (2009) KSP inhibitor ARRY-520 as a substitute for PacT. in type I ovarian cancer cells. J.Transl.Med. 7 63 PMID: 19619321
If you know of a relevant reference for ARRY 520 trifluoroacetate, please let us know.
View Related Products by Product Action
Keywords: ARRY 520 trifluoroacetate, ARRY 520 trifluoroacetate supplier, ARRY520, trifluoroacetate, potent, selective, kinesin, spindle, protein, KSP, inhibitors, inhibits, antitumor, degrades, Mcl-1, Filanesib, Kinesin, Bcl-2, Family, 4676, Tocris Bioscience
1 Citation for ARRY 520 trifluoroacetate
Citations are publications that use Tocris products. Selected citations for ARRY 520 trifluoroacetate include:
Mues et al (2019) High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Rep 27 631 PMID: 30970263
Do you know of a great paper that uses ARRY 520 trifluoroacetate from Tocris? Please let us know.
Reviews for ARRY 520 trifluoroacetate
Average Rating: 5 (Based on 1 Review.)
Have you used ARRY 520 trifluoroacetate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cell Cycle and DNA Damage Research Product Guide
This product guide provides a review of the cell cycle and DNA damage research area and lists over 170 products, including research tools for:
- Cell Cycle and Mitosis
- DNA Damage Repair
- Targeted Protein Degradation
- Ubiquitin Proteasome Pathway
- Chemotherapy Targets